
Prima BioMed

Annual General Meeting **CEO** Presentation

November 25, 2015



Notice: Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



2015 Highlights – a Transformative Year!

Planning of 2 new trials – EMA scientific advice

Announcement of Final CVac[™] OS data

Ridgeback \$15M placement

SPP \$10M placement

Partners beginning trials (GSK and Novartis)

New patent filings

New Collaborations – NEC/Yamaguchi



🖹 EDISON

Prima Biomed

IMP321 set to progress into Phase IIb study

Prime biomed is well predicted to profit functed with the cloid development of the promiting LMO2 programme following an A225m functioning and encouraging sciencific cloids from the BMA for the sponsing Plane is their of MP211 in metadatic lensed cancer. Neurofile and OSA have metadity conserved of biolativity of partnerse LMO2 programmes, providing additional walkation for the LMO2 sciencing the Prime cloids and the SPI science and the space of the Prime A227m (part A218m) with the inclusion of the Neural LMO2 programmes, the RMD of the SPI science and the service la LMO2 programmes of the LT has entered by child, and an enaboration ladiation to MP227.

Terrent	Sec. 1	100		81		100
0014	20	(13)	(100)	6.00	NA.	-
0675	1.1	(128)	(1.82)	0.00	NO. N	10
09116	11	(162)	(0.821	0.00	NA.	10
06 Ue	13	0440	(2.72)	6.00	10.5	10

Novartic moves IMP701 programme into the oligio

Novesta has insteade a Presen trial (AGD), is humanised weaton million service has insteade a Presen trial (AGD), is humanised weaton million service and trial (AGD) is not output to a moder of insteade service Novesta with the IAGDS in output patients both as a single agent and in contained and its instrume steepoint inhibit PGRD1, undersoning the patients benefits at a wear too support (ARD).

IMP321 Phase lib trial in breast cancer to start G416

Prima is policed to initiate a Prace Ito trial of lead product IMP201 (a soluble LAG3 failor proheigh in combination with chemistenegy in messatistic these second contrib. The European equators (RMA) subgraves that the initial control auficiants apport a marketing autonation of a marketine certain chickal exploriter. The failure is equator to take the resperses, on emails and lead in the Prima kine plane to launch a Phane i study of MP201 in combination with an anti-PCO1 immune checkpoint initiation in encourse patients in lead y 2016.

Ridgeback funding approved - funded to late 2016

Prima haa malaad Addiim alnoo kiing Jinkuding Adridim from Ridgeback Capital (pouuding Adrid 75m in connecties modes, approved by draweldnies in Juhij and ar Addins SRP Finna novima the resources to initiate the jukeat Prease in the fol SRP bit in segarated, breast cancer and a Prease I sambadan tati. The company inclinated that it has aufiliated and han of pando graduated and itse 2019.


Valuation: Increased to A\$271m, 13o per chare

We have increased our valuation to A3271m (prev A3168m), with the largest contributions to the increase being the inclusion of the Novertis (A302 programme or that it have where the online, and another to include the S27C. Our valuation is equal to 1% previate on an unclude change (st 1%), or its per share on an unclude change. We change the operating the operating the share accounting the obligation that online (st 1%).

Prime Biomed is a research client of Edison Investment Research Limited

E H.C.WAINWRIGHT&CO. Prime Biomed Ltd. (PBMD) Rating: Buy Retire: Buy Retire

Leading the LAG-3 Race; Initiating with a Buy and \$3.00 PT



Priors Richard is a leader in LAG-2 berughes. Instructionspise, and his obvious tradition (CPM) the migrate the set function, are involution (CPM) the migrate the set function, are involutionary beach in (Syster), Australia, is a developing the set of the set of

Active

the new

marketing of

Prima story

Oliviani undate

Pharma & biotech

Market car

-

Territoria and

one canital anders. MP121 he cancer

and the matching both of soil

.

A80.10 A80.00

0.0 0.0

See Sec

Sec. Sec.

Direct Internet

Next events

The last state in

Analysis

Same Line

D Denis Halls

Children Theory

Set MP 321 weblinder Pro-

-

.....

....

.....

AZ

A\$117m

Unique exist brackly applicable threghts, the competitor product inder development als modely applicable tables append LAG 3 commonly the second second second second second second (MH-201) of the second second second second second second sphere is independent of immunotherapy is that the immunotional function of LAG 3, we believe that these trends could possible to do a CLAG 3, we believe that these trends could possible to add to make a source and addominant diseases to resource show the initial indications of mich and messation therefore (MH-201) monotonic and long councer (MH-201) and severe spontals (MH-201) is not financial projections. Any meincludious tepportals would be an update to our projections.

Veluation, Ven derived our 12-month pine tropp of \$10.00 per Ultration ADD based on the servings of the outsides in methods: In pine sales multiple evolvate analysis of the multiple to and 2005 rais-adjusted evolvage multiple analysis applying an 15k multiple to an 2005 exciting multiple analysis applying an 15k multiple to any 2005 exciting analysis analysis applying an 15k multiple to any 2005 exciting analysis analysis applying an 15k multiple to any 2005 exciting analysis analysis applying an 15k multiple to any 2005 exciting analysis analysis analysis and and an analysis and and an analysis exciting analysis analysis analysis and the analysis and analysis exciting analysis analysis and analysis and analysis exciting analysis analysis and analysis exciting analysis analysis and analysis exciting analysis analysis exciting analysis analysis exciting analysi


For definitions and the distribution of analysis ratings, analysis and traditions, and other disclosures, please rate to pages 20 - 21 of the report

We have raised Prima's market profile

Improved market standing Institutional and independent sell-side interest



Our stock is now actively traded in the US








Prima attracting institutional grade

- Market cap now >US\$70m
- Specialist healthcare funds now on register
- ~30% of stock now held in ADRs





Prima SP YTD benchmark





Participation at Investor and Industry Events

Investor Meetings

- Multiple Roadshows
- JP Morgan Jan 2015
- Bioshares July 2015
- Rodman & Renshaw Sep 2015
- Leerink Sept 2015


Business Development

- AusBiotech Oct 2015
- BioEurope Nov 2015
- Multiple other contacts

Scientific Conferences

- ASCO May 2015
- SITC Nov 2015
- Checkpoint Conf Nov 2015







Immune Checkpoints


- Checkpoints are hot Prof Frédéric Triebel interviewed about LAG-3 in Nature Biotechnology interview – published July 2015 (Volume 15pp673-675)
- Immune checkpoints are junctions in immune signalling mechanisms between cells where decisions are made – make good targets for therapies



IMP321

Soluble dimeric recombinant form of LAG-3 (fusion protein)





- Highly efficacious in multiple animal models of cancer and infectious disease
- Shown to be safe, non-immunogenic and efficacious in humans
- At low doses can be used as a T cell adjuvant for cancer vaccines (Clin Cancer Res. 2008 Jun 1;14(11):3545-54)

Chemo-Immunotherapy: IMP321

Treatment of cancer cells with chemotherapy, radiotherapy or other drugs will kill off the cells causing tumour debris to be created and antigen release.

Adding an APC activator like IMP321 post cancer treatment enhances antigen uptake by APC's. They then migrate to lymph nodes and present a wide range of cancer antigens to CD8 T cells which then actively seek and destroy tumours.



Other Applications: IMP321


IMP321 can be combined with other immune checkpoint treatments to help drive optimal immune responses to cancer (eg upcoming combo study)

IMP321 can be used as an adjuvant in vaccine combination studies where it helps to boost the magnitude of an antigen specific response (e.g. NEC/Yamaguchi collaboration)



Upcoming trials

- AIPAC
- Ph I Combo pilot



Planned Phase IIb Chemoimmunotherapy in MBC: AIPAC trial

- Multicentre, randomised, double blind, placebocontrolled
- 15 + 196 patients: IMP321 + paclitaxel
 vs. paclitaxel + placebo
- Primary objective: efficacy (as Progression-Free Survival)
- Scientific advice from EMA received in July 2015
- Trial initiation expected in Q4 2015
- Belgium regulatory approval received in October 2015



Planned Phase I Study in Immuno-Oncology Combination

- Multicentre, open label, dose escalation
- Up to 30 patients with unresectable or metastatic melanoma
- IMP321 + Anti-PD-1 combination study
- Primary objective: safety, tolerability
- Trial initiation expected in Q1 2016



Major Addressable Markets in MBC





Metastatic Breast Cancer

- Annual global incidence of 1.67M new cases of all breast cancer
- Standard of care is variable but includes hormone therapy, chemotherapy and targeted therapies.
- We are specifically targeting Her2- cancer; refractory to hormone therapy.
- Five year survival rate is 22% (American Cancer Society)
- Sales of all breast cancer drugs are estimated to grow from \$9.8Bn to \$18.2Bn/year by 2023 (<u>Pharmatimes</u>, 2015)



Partnership Updates



IMP731 for Autoimmune Diseases



GSK's investigational product, GSK2831781, which is derived from IMP731 antibody, aims to kill the few activated LAG-3+ T cells that are autoreactive in autoimmune disease leading to long term disease control without generalised immune suppression

- GlaxoSmithKline holds exclusive WW rights to IMP731
- Jan 2015: Prima announced a single-digit million US\$ milestone
- Up to €64m in total upfront and milestones + royalties
- GSK2831781 in Phase I trials with potential regulatory filing expected within 2021-2025 timeframe (See from slide 108 of <u>GSK investor</u> presentation
- Phase II expected to initiate in 2016



U NOVARTIS

IMP701: Antagonist

mAb

IMP701 is an anti-LAG-3 antibody that blocks LAG-3-mediated immune down-regulation


LAG-3 is a prime target for immune checkpoint blockade as it is readily expressed at a high level in many human tumours.

- Novartis holds exclusive WW rights
- Aug 2015: Start of Phase 1 study by Novartis (Novartis milestone payment to be received for IMP701 Phase 1 initiation)
- LAG-525 to be used in combination with PD-1 in solid tumours before end of this year

(See slide 10 of Novartis IR presentation)



Other Partnerships



Upcoming Milestones

Clinical


- Q4 2015: Initiation of AIPAC (metastatic breast cancer) // First data in 2016 (e.g. safety/PK)
- Q1 2016: Initiation of Anti-PD-1 combination Phase I study (melanoma) // First data in 2016(e.g. safety/PK)
- Expected commencement of Phase II study with IMP731 (GSK)
- Continued development of Phase I study IMP701 (Novartis)

Other

- Ongoing discussions re CVac
- Strategic partnering and collaboration discussions re IMP321
- Progress in IP
- Ongoing investor relations efforts



A solid foundation







Thank you!